The collaboration plans to evaluate the combination of Marengo's first-in-class TCR Vβ selective dual T cell agonist, STAR0602 (Invikafusp alfa), with Trodelvy (sacituzumab govitecan-hziy) Gilead's Trop-2 directed ADC in a new multi-center Phase I/II clinical study (START-002).
The planned combination trial, sponsored by Marengo, is expected to commence soon. This study will evaluate the safety, tolerability, and preliminary efficacy of STAR0602 (Invikafusp alfa) in combination with Trodelvy in patients with metastatic TNBC or metastatic HR+/HER2- breast cancer, aiming to explore a novel therapeutic strategy that could offer new treatment options for patients.
Under the clinical study collaboration and supply agreement, Gilead will provide Trodelvy to Marengo, who will conduct and sponsor the combination study. Marengo and Gilead will retain all development and commercial rights to their respective compounds, including as monotherapy or as combination therapies.
The collaboration plans to evaluate the combination of Marengo's first-in-class TCR Vβ selective dual T cell agonist, STAR0602 (Invikafusp alfa), with Trodelvy (sacituzumab govitecan-hziy) Gilead's Trop-2 directed ADC in a new multi-center Phase I/II clinical study (START-002).
該合作計劃評估Marengo的首創TCRVβ選擇性雙T細胞激動劑STAR0602（Invikafusp alfa）與Trodelvy（sacituzumab govitecan-hziy）Gilead的Trop-2引導的ADC在新的多中心I/II期臨床研究（STARt-002）中的組合。
The planned combination trial, sponsored by Marengo, is expected to commence soon. This study will evaluate the safety, tolerability, and preliminary efficacy of STAR0602 (Invikafusp alfa) in combination with Trodelvy in patients with metastatic TNBC or metastatic HR+/HER2- breast cancer, aiming to explore a novel therapeutic strategy that could offer new treatment options for patients.
由Marengo贊助的計劃中的組合試驗預計將很快開始。該研究將評估STAR0602（Invikafusp alfa）與Trodelvy在轉移性TNBC或轉移性HR+/HER2-乳腺癌患者中的安全性、耐受性和初步療效，旨在探索一種新的治療策略，爲患者提供新的治療選擇。
Under the clinical study collaboration and supply agreement, Gilead will provide Trodelvy to Marengo, who will conduct and sponsor the combination study. Marengo and Gilead will retain all development and commercial rights to their respective compounds, including as monotherapy or as combination therapies.
根據臨床研究合作和供應協議，Gilead將向Marengo提供Trodelvy，Marengo將進行和贊助組合研究。Marengo和Gilead將保留各自化合物的所有開發和商業權利，包括作爲單藥治療或其他聯合療法。
